Literature DB >> 25839661

Heparinase I-specific disaccharide unit of heparin is a key structure but insufficient for exerting anti-prion activity in prion-infected cells.

Kenta Teruya1, Masahiro Wakao2, Masaki Sato2, Taichi Hamanaka1, Keiko Nishizawa1, Yukino Funayama1, Yuji Sakasegawa1, Yasuo Suda2, Katsumi Doh-ura3.   

Abstract

Glycosaminoglycans reportedly play important roles in prion formation, but because of their structural complexity, the chemical structures affecting prion formation have not been fully evaluated. Here, we compared two types of low molecular weight heparins and found that heparinase I-sensitive structures influenced anti-prion activity in prion-infected cells. Surface plasmon resonance analyses showed significant binding of a representative heparinase I substrate disaccharide unit, GlcNS6S-IdoA2S, to recombinant prion protein (PrP) fragments, such as full-length PrP23-231 and N-terminal domain PrP23-89, but not to PrP89-230. This binding was competitively inhibited by heparin or pentosan polysulfate, but not by Cu(2+). These PrP binding profiles of the disaccharide unit are consistent with those previously reported for heparin. However, synthetic compounds comprising disaccharide unit alone or its multimers exhibited no anti-prion activity in prion-infected cells. Consequently, the findings suggest that the heparin disaccharide unit that binds to the N-terminal region of PrP is a key structure, but it is insufficient for exerting anti-prion activity.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anti-prion; Glycosaminoglycan; Heparinase; Low molecular weight heparin; Prion; Surface plasmon resonance

Mesh:

Substances:

Year:  2015        PMID: 25839661     DOI: 10.1016/j.bbrc.2015.03.139

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

1.  Melanin or a Melanin-Like Substance Interacts with the N-Terminal Portion of Prion Protein and Inhibits Abnormal Prion Protein Formation in Prion-Infected Cells.

Authors:  Taichi Hamanaka; Keiko Nishizawa; Yuji Sakasegawa; Ayumi Oguma; Kenta Teruya; Hiroshi Kurahashi; Hideyuki Hara; Suehiro Sakaguchi; Katsumi Doh-Ura
Journal:  J Virol       Date:  2017-02-28       Impact factor: 5.103

Review 2.  Therapeutic development of polymers for prion disease.

Authors:  Kenta Teruya; Katsumi Doh-Ura
Journal:  Cell Tissue Res       Date:  2022-03-21       Impact factor: 5.249

3.  A synthetic heparinoid blocks Tau aggregate cell uptake and amplification.

Authors:  Barbara E Stopschinski; Talitha L Thomas; Sourena Nadji; Eric Darvish; Linfeng Fan; Brandon B Holmes; Anuja R Modi; Jordan G Finnell; Omar M Kashmer; Sandi Estill-Terpack; Hilda Mirbaha; Hung S Luu; Marc I Diamond
Journal:  J Biol Chem       Date:  2020-01-23       Impact factor: 5.157

Review 4.  Exploring Anti-Prion Glyco-Based and Aromatic Scaffolds: A Chemical Strategy for the Quality of Life.

Authors:  María Teresa Blázquez-Sánchez; Ana M de Matos; Amélia P Rauter
Journal:  Molecules       Date:  2017-05-24       Impact factor: 4.411

5.  Pentosan polysulfate induces low-level persistent prion infection keeping measurable seeding activity without PrP-res detection in Fukuoka-1 infected cell cultures.

Authors:  Hanae Takatsuki; Morikazu Imamura; Tsuyoshi Mori; Ryuichiro Atarashi
Journal:  Sci Rep       Date:  2022-05-13       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.